Back to top
more

uniQure (QURE)

(Delayed Data from NSDQ)

$4.76 USD

4.76
457,327

-0.28 (-5.56%)

Updated May 23, 2024 04:00 PM ET

After-Market: $4.76 0.00 (0.00%) 5:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for QURE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

uniQure N.V. [QURE]

Reports for Purchase

Showing records 61 - 80 ( 153 total )

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 61

04/30/2019

Company Report

Pages: 11

Lull in Near-Term Clinical Readouts Weighs on Stock Creating Longer-Term Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 62

03/01/2019

Company Report

Pages: 12

With Hemophilia B Potentially in the Bag, the Focus Is Now on Expanding a Differentiated Clinical-Stage Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 63

02/25/2019

Company Report

Pages: 12

SPARK-ing a Rush Into QURE-ative Therapies

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 64

02/11/2019

Company Report

Pages: 10

Gene Therapy Pedigree in Display; Psst! Pfizer, It''s Never too Late to Cut Losses; Target Goes to $73

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 65

01/14/2019

Company Report

Pages: 11

Multiple Irons in the Fire Are Supported by Commercial Scale Manufacturing; What''s Not to Like?

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 66

12/04/2018

Company Report

Pages: 10

Vectors Matter; and AAV5 Has a Lot Going for It

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 67

11/26/2018

Company Report

Pages: 12

Our Thoughts on Pipeline Augmentation; Target Increased to $60

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 68

11/15/2018

Daily Note

Pages: 10

FIX Numbers Speak Louder Than Words

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 69

11/07/2018

Company Report

Pages: 10

3Q18 Corporate Update With Focus on November 19, 2018, R-D Day

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 70

10/19/2018

Company Report

Pages: 10

A Next-Gen Promoter at the ESGCT; Likely Signals Unveiling for Hemophilia A Program at the November 19 R-D Day

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 71

10/11/2018

Company Report

Pages: 10

Risk Reward Looking Increasingly Favorable Heading Into November 19, 2018, R-D Day

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 72

09/24/2018

Company Report

Pages: 10

Dosing Completion on Schedule Bodes Well for the Clinical Readout; Target Increased to $48 From $42

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 73

09/10/2018

Daily Note

Pages: 15

Pre-ASH Catalyst Calendar For Stocks Under Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 74

08/23/2018

Daily Note

Pages: 9

Buckle Up-Dose Confirmation Data From AMT-061 on Schedule Prior to ASH 2018 by Our Estimates

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 75

08/09/2018

Company Report

Pages: 10

Better Mouse Trap With the AAV5 Vector; 4Q18 Clinical Validation Could Spark a Recovery

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 76

07/17/2018

Company Report

Pages: 9

Take Advantage of a Potentially Irrational Selloff

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 77

07/16/2018

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 78

06/29/2018

Company Report

Pages: 9

First off the Blocks Likely to Translate Into Meaningful Commercial Advantage for Once-and Done Gene Therapy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 79

05/22/2018

Company Report

Pages: 9

Something Unique About AAV5; Target Revised Higher

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 80

05/01/2018

Company Report

Pages: 9

Transformation Continues; Besting Timelines and Regaining Credibility

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party